Skip to content

CEREBAIN BIOTECH CORP.: 10-Q filed 2014-02-10

What CEREBAIN BIOTECH CORP. reported in its quarterly report filed 2014-02-10 (fiscal Q2 2014): 25 published measures, 72 facts as tagged in accession 0001477932-14-000591.

This filing

Form
10-Q (quarterly report)
Filed
2014-02-10
Fiscal period
fiscal Q2 2014
Accession
0001477932-14-000591 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All CEREBAIN BIOTECH CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-311,056,398USD
At 2013-06-3085,441USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-12-31763,653USD
At 2013-06-30944,273USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-31292,745USD
At 2013-06-30-858,832USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-12-31103,998USD
At 2013-06-308USD
At 2012-12-3110,357USD
At 2012-06-304,185USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-854,785USD92
2013-07-01 to 2013-12-31-1,580,432USD184
2010-02-22 to 2013-12-31-4,366,461USD1409
2012-10-01 to 2012-12-31-67,549USD92
2012-07-01 to 2012-12-31-353,308USD184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-07-01 to 2013-12-31-462,042USD184
2010-02-22 to 2013-12-31-1,837,657USD1409
2012-07-01 to 2012-12-31-163,828USD184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2010-02-22 to 2013-12-310USD1409

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-07-01 to 2013-12-31566,032USD184
2010-02-22 to 2013-12-311,970,666USD1409
2012-07-01 to 2012-12-31170,000USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2010-02-22 to 2013-12-31-29,011USD1409

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2013-10-01 to 2013-12-3133,816,414shares92
2013-07-01 to 2013-12-3132,927,827shares184
2012-10-01 to 2012-12-3131,180,001shares92
2012-07-01 to 2012-12-3131,180,001shares184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-854,785USD92
2013-07-01 to 2013-12-31-1,580,432USD184
2010-02-22 to 2013-12-31-4,366,461USD1409
2012-10-01 to 2012-12-31-67,549USD92
2012-07-01 to 2012-12-31-353,308USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-12-31972,498USD
At 2013-06-301,541USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-10-01 to 2013-12-3143,709USD92
2013-07-01 to 2013-12-3163,328USD184
2010-02-22 to 2013-12-3188,431USD1409
2012-10-01 to 2012-12-318,100USD92
2012-07-01 to 2012-12-3114,850USD184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-31415,005USD
At 2013-06-30625,155USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-12-3170,758USD
At 2013-06-3081,154USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-10-01 to 2013-12-31687,428USD92
2013-07-01 to 2013-12-311,310,368USD184
2010-02-22 to 2013-12-313,532,363USD1409
2012-10-01 to 2012-12-3142,574USD92
2012-07-01 to 2012-12-31304,708USD184

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2013-10-01 to 2013-12-31564,700USD92
2013-07-01 to 2013-12-311,046,099USD184
2010-02-22 to 2013-12-313,150,170USD1409
2012-10-01 to 2012-12-3142,431USD92
2012-07-01 to 2012-12-31195,851USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-12-3136,230,953shares
At 2013-06-3031,580,001shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-12-314,622,975USD
At 2013-06-301,895,617USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-12-3187,184USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-854,785USD92
2013-07-01 to 2013-12-31-1,580,432USD184
2010-02-22 to 2013-12-31-4,366,461USD1409
2012-10-01 to 2012-12-31-67,549USD92
2012-07-01 to 2012-12-31-353,308USD184

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2010-02-22 to 2013-12-311,711USD1409
2012-10-01 to 2012-12-31143USD92
2012-07-01 to 2012-12-31357USD184

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2010-02-22 to 2013-12-311,711USD1409
2012-07-01 to 2012-12-31357USD184

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2010-02-22 to 2013-12-31791,884USD1409

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-07-01 to 2013-12-31-10,396USD184
2010-02-22 to 2013-12-3170,758USD1409
2012-07-01 to 2012-12-3134,006USD184

Inspect the source

Entity
CEREBAIN BIOTECH CORP. / CIK 0001453099
Captured
SEC response SHA-256
9fdf4c3b2bb6536cc10c8e24af596aaa762e0560a25fd29c07e252f58d07262f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001453099.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))